Theravance Biopharma, Inc. (NASDAQ:TBPH) Stock Has Consensus Target Price of $19.40 According to Analysts

Theravance Biopharma, Inc. (NASDAQ:TBPH) has received a consensus rating of “Hold” from the eight ratings firms that are presently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold recommendation. The average 1 year price objective among brokers that have covered the stock in the last year is $19.40.

A number of equities research analysts have recently commented on TBPH shares. HC Wainwright cut shares of Theravance Biopharma from a “buy” rating to a “neutral” rating and increased their price target for the company from $15.00 to $17.00 in a report on Tuesday, July 7th. JonesTrading cut Theravance Biopharma from a “buy” rating to a “hold” rating in a research report on Monday, June 29th. Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, August 17th. Zacks Research downgraded Theravance Biopharma from a “strong-buy” rating to a “hold” rating in a report on Monday, September 7th. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Theravance Biopharma in a research report on Thursday, September 24th.

Insider Activity

In other news, major shareholder Eli Samaha sold 37,799 shares of Theravance Biopharma stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $17.00, for a total value of $642,583.00. Following the completion of the sale, the insider directly owned 9,174,453 shares in the company, valued at $155,965,701. The trade was a 0.41% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Rhonda Farnum sold 13,314 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $17.03, for a total transaction of $226,737.42. Following the transaction, the senior vice president directly owned 213,476 shares of the company’s stock, valued at $3,635,496.28. The trade was a 5.87% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 7.65% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Theravance Biopharma

Several institutional investors and hedge funds have recently added to or reduced their stakes in TBPH. Caitong International Asset Management Co. Ltd raised its stake in Theravance Biopharma by 51.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 4,133 shares of the biopharmaceutical company’s stock valued at $77,000 after buying an additional 1,408 shares during the last quarter. Allspring Global Investments Holdings LLC purchased a new position in shares of Theravance Biopharma in the 1st quarter worth $171,000. Globeflex Capital L P bought a new stake in shares of Theravance Biopharma in the first quarter worth $171,000. Cannon Global Investment Management LLC bought a new stake in shares of Theravance Biopharma in the first quarter worth $260,000. Finally, Financiere des Professionnels Fonds d investissement inc. purchased a new stake in Theravance Biopharma during the first quarter valued at $268,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Stock Performance

NASDAQ TBPH opened at $17.03 on Tuesday. Theravance Biopharma has a 12 month low of $13.08 and a 12 month high of $21.03. The stock’s fifty day moving average price is $16.97 and its 200-day moving average price is $16.52. The stock has a market cap of $884.18 million, a P/E ratio of 16.86 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.18). The firm had revenue of $20.73 million during the quarter, compared to the consensus estimate of $22.49 million. Theravance Biopharma had a negative return on equity of 0.77% and a net margin of 51.58%. As a group, analysts forecast that Theravance Biopharma will post 1.56 earnings per share for the current fiscal year.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company’s work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.